ZNA-1041 by F. Hoffmann-La Roche for Solid Tumor: Likelihood of Approval
Pharmaceutical Technology
MAY 31, 2023
ZNA-1041 is under clinical development by F. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Let's personalize your content